Ann-Marie Svensson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1495447/publications.pdf

Version: 2024-02-01

70 papers 5,290 citations

249298 26 h-index 70 g-index

70 all docs

70 docs citations

times ranked

70

7780 citing authors

#	Article	IF	CITATIONS
1	Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes. Diabetes Care, 2022, 45, 127-133.	4.3	7
2	The comparative cardiovascular and renal effectiveness of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: A Scandinavian cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 473-485.	2.2	13
3	Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study. Diabetes Care, 2022, 45, e93-e96.	4.3	3
4	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabetic Medicine, 2022, 39, e14766.	1,2	28
5	The impact of diabetes mellitus on major amputation among patients with chronic limb threatening ischemia undergoing elective endovascular therapy- a nationwide propensity score adjusted analysis. Journal of Diabetes and Its Complications, 2021, 35, 107675.	1.2	6
6	Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls. Diabetologia, 2021, 64, 1595-1603.	2.9	34
7	Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study. Journal of the American Heart Association. 2021. 10. e019323.	1.6	28
8	Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovascular Diabetology, 2021, 20, 67.	2.7	27
9	Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study. Diabetologia, 2021, 64, 1973-1981.	2.9	19
10	Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections. Diabetes Technology and Therapeutics, 2021, 23, 425-433.	2.4	3
11	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia, 2021, 64, 2001-2011.	2.9	22
12	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia, 2021, 64, 2204-2214.	2.9	9
13	Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes. Diabetes Therapy, 2021, 12, 2371-2386.	1.2	5
14	Development of a life expectancy table for individuals with type 1 diabetes. Diabetologia, 2021, 64, 2228-2236.	2.9	10
15	Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register. Cardiovascular Diabetology, 2021, 20, 173.	2.7	14
16	Risk factors and incidence over time for lower extremity amputations in people with type 1 diabetes: an observational cohort study of 46,088 patients from the Swedish National Diabetes Registry. Diabetologia, 2021, 64, 2751-2761.	2.9	13
17	Cost-Effectiveness of the FreeStyle Libre® System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden. Diabetes Therapy, 2021, 12, 3137-3152.	1,2	9
18	Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovascular Diabetology, 2021, 20, 202.	2.7	19

#	Article	IF	Citations
19	Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Therapy, 2021, 12, 3093-3105.	1.2	3
20	Organisation of primary diabetes care in people with type 2 diabetes in relation to all-cause mortality: A nationwide register-based cohort study. Diabetes Research and Clinical Practice, 2020, 167, 108352.	1.1	1
21	A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes. Diabetes Care, 2020, 43, 1741-1749.	4.3	12
22	Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits. Diabetes Care, 2020, 43, 1276-1284.	4.3	43
23	Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. Diabetes Therapy, 2020, 11, 1807-1820.	1.2	8
24	Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey. Diabetes Therapy, 2020, 11, 725-734.	1.2	3
25	Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovascular Diabetology, 2020, 19, 9.	2.7	70
26	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ, The, 2020, 369, m1186.	3.0	63
27	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. Diabetes Care, 2020, 43, 1326-1335.	4.3	41
28	Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register. BMJ Open Diabetes Research and Care, 2020, 8, e000719.	1.2	7
29	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2019, 17, 2769-2775.e4.	2.4	37
30	HbA _{1c} level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ: British Medical Journal, 2019, 366, 14894.	2.4	109
31	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ: British Medical Journal, 2019, 366, 14772.	2.4	69
32	Risk Factors for Atrial Fibrillation in People With Type 1 Diabetes: An Observational Cohort Study of 36,258 Patients From the Swedish National Diabetes Registry. Diabetes Care, 2019, 42, 1530-1538.	4.3	16
33	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000602.	1.2	17
34	Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction. Circulation, 2019, 139, 2380-2382.	1.6	2
35	Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey. Diabetes Therapy, 2019, 10, 1523-1530.	1.2	8
36	Early Clinical Indicators of Addison Disease in Adults With Type 1 Diabetes: A Nationwide, Observational, Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1148-1157.	1.8	4

#	Article	IF	Citations
37	Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation, 2019, 139, 1900-1912.	1.6	108
38	Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Open Heart, 2019, 6, e000967.	0.9	5
39	Associations between quality of work features in primary health care and glycaemic control in people with Type 2 diabetes mellitus: A nationwide survey. Primary Care Diabetes, 2019, 13, 176-186.	0.9	1
40	Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study. BMJ Open, 2019, 9, e023882.	0.8	25
41	Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes. Open Heart, 2018, 5, e000727.	0.9	11
42	Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies. European Journal of Endocrinology, 2018, 178, 113-120.	1.9	19
43	Resources and organisation in primary health care are associated with HbA 1c level: A nationwide study of 230 958 people with Type 2 diabetes mellitus. Primary Care Diabetes, 2018, 12, 23-33.	0.9	7
44	Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia, 2018, 61, 2300-2309.	2.9	31
45	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2018, 379, 633-644.	13.9	888
46	Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet, The, 2018, 392, 477-486.	6.3	492
47	Range of Risk Factor Levels. Circulation, 2017, 135, 1522-1531.	1.6	102
48	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine, 2017, 376, 1407-1418.	13.9	880
49	PCI Versus CABG in Patients With TypeÂ1ÂDiabetesÂand Multivessel Disease. Journal of the American College of Cardiology, 2017, 70, 1441-1451.	1.2	21
50	Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart, 2017, 103, 1687-1695.	1.2	41
51	Changes in risk factors and their contribution to reduction of mortality risk following gastric bypass surgery among obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study. BMJ Open Diabetes Research and Care, 2017, 5, e000386.	1.2	9
52	Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study. European Journal of Endocrinology, 2017, 176, 31-39.	1.9	23
53	Association Between Socioeconomic Status and Mortality, Cardiovascular Disease, and Cancer in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2016, 176, 1146.	2.6	100
54	Indications for Insulin Pump Therapy in Type 1 Diabetes and Associations With Glycemic Control. Journal of Diabetes Science and Technology, 2016, 10, 1027-1033.	1.3	15

#	Article	IF	CITATIONS
55	Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. Diabetes and Vascular Disease Research, 2016, 13, 268-277.	0.9	22
56	Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia, 2016, 59, 1167-1176.	2.9	81
57	Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]. Diabetologia, 2016, 59, 863-864.	2.9	1
58	Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia, 2016, 59, 980-988.	2.9	119
59	Impact of ethnicity on progress of glycaemic control in 131 935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. BMJ Open, 2015, 5, e007599-e007599.	0.8	29
60	Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia, 2015, 58, 2259-2268.	2.9	28
61	Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. Diabetes Care, 2015, 38, 1518-1527.	4.3	61
62	Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes and Endocrinology,the, 2015, 3, 847-854.	5.5	144
63	Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden. International Journal of Environmental Research and Public Health, 2014, 11, 4939-4952.	1.2	22
64	Glycemic Control and Excess Mortality in Type 1 Diabetes. New England Journal of Medicine, 2014, 371, 1972-1982.	13.9	717
65	Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden. Diabetes Care, 2014, 37, 2974-2981.	4.3	44
66	The incidence of diabetes among 0–34Âyear olds in Sweden: new data and better methods. Diabetologia, 2014, 57, 1375-1381.	2.9	87
67	Glycaemic control and incidence of heart failure in 20â€^985 patients with type 1 diabetes: an observational study. Lancet, The, 2011, 378, 140-146.	6.3	222
68	Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes. Diabetes Care, 2010, 33, 1640-1646.	4.3	122
69	The influence of a history of diabetes on treatment and outcome in acute myocardial infarction, during two time periods and in two different countries. International Journal of Cardiology, 2007, 119, 319-325.	0.8	16
70	Influence of diabetes on longâ€ŧerm outcome among unselected patients with acute coronary events. Scandinavian Cardiovascular Journal, 2004, 38, 229-234.	0.4	15